The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure.
An article published in the European Journal of Heart Failure on March 13, 2024 titled “Efficacy and safety of the Aria pulmonary endovascular device in pulmonary hypertension” reports on the first in-man acute study to test safety and feasibility of the ARIA endovascular device. The device effectively reduced RV afterload in several forms of pulmonary hypertension. In the US in the ASPIRE PH trial that just started in February 2024 the chronic implant will be tested. To be followed.
Citation
Gerges C, Vollmers K, Skoro-Sajer N, Dannenberg V, Hartig V, Pritzker MR, Scandurra J, Weir EK, Lang IM. Efficacy and safety of the Aria pulmonary endovascular device in pulmonary hypertension. Eur J Heart Fail. 2024 Mar 13. doi: 10.1002/ejhf.3187. Epub ahead of print. PMID: 38481353.
Read more about the ASPIRE PH trial on the clinicaltrials.gov website at this link
View the article at this link on the Wiley Online Library
Disclaimer
While every possible effort will be taken to ensure that the Pulmonary Hypertension Knowledge Sharing Platform content is accurate and up-to-date, it may still include opinions of experts that are the best knowledge at the time of publication but may now be outdated, and materials that are otherwise inaccurate or incomplete. We invite visitors to consult with their health care professionals before making any decisions based upon them.